CORDIS
EU research results

CORDIS

English EN

Development of “smart” amplifiers of reactive oxygen species specific to aberrant polymorphonuclear neutrophils for treatment of inflammatory and autoimmune diseases, cancer and myeloablation.

Project information

Grant agreement ID: 861878

Status

Ongoing project

  • Start date

    1 January 2020

  • End date

    31 December 2024

Funded under:

H2020-EU.1.2.1.

  • Overall budget:

    € 2 999 998,75

  • EU contribution

    € 2 999 998,75

Coordinated by:

FRIEDRICH-ALEXANDER-UNIVERSITAET ERLANGEN-NUERNBERG

Germany

Project description

English EN

Targeted amplification of reactive oxygen species could fight serious diseases

A diet rich in antioxidants could protect against a variety of pathologies from cancer and neurological disorders to cardiovascular disease. Antioxidants soak up free radicals among which are reactive oxygen species (ROS). ROS, as their name suggests, are unstable molecules containing oxygen that easily react with other molecules in a cell. Initially considered damaging agents, we now know they also play a key role in healthy cell processes. The key seems to be in the amount of time they are present and at what levels in specific cells. NeutroCure is developing ways to control the spatial and temporal amplification of ROS generation to effectively treat severe pathological conditions characterised by a dysfunction in ROS homeostasis.

Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

FRIEDRICH-ALEXANDER-UNIVERSITAET ERLANGEN-NUERNBERG

Address

Schlossplatz 4
91054 Erlangen

Germany

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 629 000

Participants (6)

UNIVERSITY OF SURREY

United Kingdom

EU Contribution

€ 410 998,75

UNIVERSITATSKLINIKUM ERLANGEN

Germany

EU Contribution

€ 640 000

LVIVSKYI NATIONALNYI MEDYCHNYI UNIVERSYTET IMENI DANYLA HALYTSKOHO

Ukraine

EU Contribution

€ 400 000

CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CARLOS III (F.S.P.)

Spain

EU Contribution

€ 400 000

REDOXIS AB

Sweden

EU Contribution

€ 400 000

INSTITUT GUSTAVE ROUSSY

France

EU Contribution

€ 120 000

Project information

Grant agreement ID: 861878

Status

Ongoing project

  • Start date

    1 January 2020

  • End date

    31 December 2024

Funded under:

H2020-EU.1.2.1.

  • Overall budget:

    € 2 999 998,75

  • EU contribution

    € 2 999 998,75

Coordinated by:

FRIEDRICH-ALEXANDER-UNIVERSITAET ERLANGEN-NUERNBERG

Germany